Information about the vaccines
Authorised vaccines and patient information leaflet (PIL)
Vaccine Product Information
This information is a copy of the product information for COVID-19 vaccines, which outlines the conditions under which the vaccine should be used and information on its known safety.
This information may be updated, if necessary.
The MHRA is unable to offer medical advice and so if a patient has any questions about a vaccine they should contact their doctor or pharmacist. Suspected adverse reactions to a vaccine can be Yellow Card.
The Information for UK and IOM recipients document provides information for patients.
Authorised vaccines and patient information leaflet (PIL)
Spikevax vaccine
Last updated 02/03/2023 - Patient Information Leaflet for Spikevax
Spikevax Original/Bivalent BA.1
(50 micrograms/50 micrograms)/mL dispersion for injection
elasomeran/imelasomeran
Updated 02/03/2023
Comirnaty
Comirnaty original/Bivalent BA.1 (15/15 micrograms)/dose dispersion for injection
Adults and adolescents from 12 years
COVID-19 mRNA Vaccine (nucleoside modified)
Comirnaty 3 micrograms/dose concentrate for dispersion for injection
Infants and children 6 months to 4 years COVID-19 mRNA Vaccine (nucleoside modified)
Updated March 2023
Comirnaty 30 Adults and adolescents from 12 years micrograms/dose concentrate for dispersion for injection Adults and adolescents from 12 years COVID-19 mRNA Vaccine (nucleoside modified)
Updated March 2023
Comirnaty 10 Concentrate micrograms/dose concentrate for dispersion for injection
Children 5 to 11 years COVID-19 mRNA Vaccine (nucleoside modified)
Updated March 2023
Nuvaxovid
Last updated 11/2022 - Product Information Leaflet (PIL) for Nuvaxovid dispersion for injection
Updated 9 November 2022
Side effects
Blood clotting, myocarditis and pericarditis, and Guillain-Barré Syndrome (GBS)
See COVID-19 vaccination and rare side effects (gov.uk) for information and guidance on these very rare conditions reported after COVID-19 vaccination.
9 January 2023
Pregnant women who are inadvertently immunised should be notified to the Vaccine in Pregnancy surveillance programme (gov.uk).
25 August 2022
Reporting side effects
You can report any suspected side effects of vaccines and medicines through the Yellow Card scheme by calling 0800 731 6789; or registering and downloading the Yellow Card app; or online.
MHRA regular reports
The MHRA Weekly report covering adverse reactions to approved COVID-19 vaccines are published regularly.
Surveillance
Local Vaccination delivery: COVID-19 vaccine statistics (Respiratory Surveillance Report-gov.im) - includes surveillance for respiratory illness symptoms, sentinel swabbing, vaccination and mortality.
Updated weekly
Guidance: COVID-19 vaccination in pregnancy surveillance
25 November 2021
Guidance: Monitoring reports of the effectiveness of COVID-19 vaccination
1 September 2022
Research and analysis: COVID-19 vaccine weekly surveillance reports (gov.uk)
2023
As the COVID-19 programme continues to change please check items regularly for any updates or changes.
Public Health Isle of Man has adapted the information supplied by JCVI and PHE for the delivery of the COVID-19 Vaccination programme and this has been sourced from COVID-19 vaccination programme (gov.uk).
To view older leaflets and information, please visit the COVID-19 vaccination archive.
Updated 23 January 2023
